Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

Knee Osteoarthritis Clinical Trial

Official title:

A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04636229
• Other study ID #: 19 OA 001 ASA
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: December 14, 2020
• Est. completion date: March 2024

Study information

• Verified date: February 2024
• Source: Organogenesis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.

Description:

This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study of ASA in patients with OA of the knee. Initially, 474 subjects are planned for inclusion in this study using a group sequential design with two interim analyses and a final analysis. Sample size re-estimation is planned at the second interim analysis. Based on conditional power, the maximum sample size may be increased to up to 700 patients. Patients will be randomly assigned in a 1:1 ratio to receive a single intra-articular (IA) injection of 2 mL of ASA (plus 2 mL of normal saline) or 4 mL of normal saline.

Patients will be screened after informed consent is obtained. Eligible patients will be randomized to receive a single IA injection on Day 1. They will have serial assessments of knee pain, function, and symptoms scores, as well as safety assessments for up to 52 weeks after administration of the study drug.

The planned sequence and maximum duration of the study periods will be as follows:

• Screening: 2 weeks

• Treatment: 1 day

• Follow-up: 52 weeks

The maximum treatment duration for each patient is 1 day.

The maximum study duration for each patient is 54 weeks.

Efficacy will be assessed via Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) responder rates.

Safety will be assessed via monitoring of adverse events (AEs), safety laboratory testing, vital signs, physical examination, and concomitant medication use.

An independent data monitoring committee (DMC) with a defined charter will review study data and make preliminary decisions relative to interim analyses.

The assessments that are used in this study are standard, and are generally recognized as reliable, accurate, and relevant.

No pediatric patients will be included as OA of the knee is an age-related disorder and rarely occurs in patients under the age of 18 years. The sponsor plans to submit a waiver for studies in all pediatric age subgroups.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 474
• Est. completion date: March 2024
• Est. primary completion date: July 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males or females 18 years of age or older

2. Diagnosis of OA of the knee by a combination of clinical and radiographic findings

3. OA of the knee with Kellgren and Lawrence radiographic classification (Grade 2-4 inclusive) confirmed by posterior-anterior, weight-bearing, fixed flexion radiography with 10° caudal beam angulation. A specially designed positioning frame will be used to standardize the positioning for image acquisition.

4. Patients who have failed to adequately respond for at least 6 months to at least 2 OA therapies that include conservative, non-pharmacological therapy and simple analgesics (e.g., acetaminophen); nonsteroidal anti-inflammatory drugs (NSAIDS); avoidance of activities that cause joint pain; exercise; weight loss; physical therapy; and removal of excess fluid from the knee

5. Overall pain score over the previous 7 days of 11 or more on the WOMAC Pain scale.

6. Body mass index (BMI) < 40 kg/m²

7. If female, must be postmenopausal (for at least 2 years), surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), sexually abstinent, or willing and able to use 2 methods of contraception from Day 1 through 12 months after treatment

8. Males who are not surgically sterile (vasectomy) for at least 6 months prior to screening must confirm their willingness to use adequate methods of contraception from Day 1 through 12 months after treatment

9. Willing to agree not to use illicit drugs during the study, and to have illicit drug testing at screening and at later time points, if illicit drug use is suspected during the study

10. Able to comply with study requirements and complete the full sequence of protocol-related procedures and evaluations, including post-hospitalization, out-patient, and follow-up visits

11. Able to understand and provide written informed consent

Exclusion Criteria:

1. Use of pain medication (including NSAIDs and cannabidiol [CBD] oil) less than 15 days before treatment (acetaminophen allowed)

2. Regular use of anticoagulants

3. Symptoms of locking, intermittent block to range of motion, or loose body sensation that could indicate meniscal displacement or an IA loose body

4. Corticosteroid injection into the index knee within 3 months prior to screening

5. Viscosupplement (e.g., hyaluronic acid [HA]) injection, platelet-rich plasma injection, bone marrow aspirate (BMA) or bone marrow aspiration concentrate (BMAC), placental-derived tissue/cells, adipose tissue, or any other autologous or allogeneic product into the index knee within 6 months prior to screening

6. Patients with known hypersensitivity reactions to ASA or any of its constituents (e.g., HA, dimethyl sulfoxide [DMSO])

7. Knee surgery on the index knee within 12 months prior to screening and/or planned knee surgery during the study

8. Knee surgery on the contralateral knee within 6 months prior to screening and/or planned knee surgery during the study

9. Acute index knee trauma within 3 months prior to screening

10. Knee effusion requiring aspiration of the index or contralateral knee within 3 months prior to screening

11. Contralateral knee pain = 4 on the WOMAC Pain scale on most days during the past week.

12. Current therapy with any immunosuppressive therapy, including corticosteroids (> 5 mg/day of prednisone)

13. Clinically significant findings on the screening laboratory tests or physical examination that are not specific to OA of the knee and may interfere with study conduct or interpretation of data or increase patient risk

14. Clinically significant intercurrent illness, medical condition, non-knee pain, or medical history (including neurological or mental illness, human immunodeficiency virus, fibromyalgia, complex regional pain syndrome, or any active infection, including hepatitis B or C) that could jeopardize the patient safety, limit participation, or compromise interpretation of data derived from the patient

15. Active alcohol or substance use disorder, or any other reason that would make it unlikely for the patient to comply with study procedures

16. Females who are pregnant (positive pregnancy test at screening or prior to treatment) or lactating

17. Participation in another clinical trial within the 30 days (or 5 half-lives of the investigational compound, whichever is longer) before screening

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Biological:
• Amniotic Suspension Allograft
This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.

Drug:
• Placebo
Matching placebo is 0.9% normal saline: 4 mL to be injected IA.

Locations

Country	Name	City	State
United States	Lehigh Center for Clinical Research	Allentown	Pennsylvania
United States	University Orthopedics Center	Altoona	Pennsylvania
United States	AARDS Research, Inc.	Aventura	Florida
United States	Sinai Hospital of Baltimore	Baltimore	Maryland
United States	Alabama Clinical Therapeutics	Birmingham	Alabama
United States	Central Research Associates	Birmingham	Alabama
United States	Injury Care Research	Boise	Idaho
United States	Tufts Medical Center	Boston	Massachusetts
United States	Cedar Health Research, LLC	Burleson	Texas
United States	Chicago Clinical Research Institute Inc	Chicago	Illinois
United States	Rush University Medical Center	Chicago	Illinois
United States	Spectrum Medical, Inc	Danville	Virginia
United States	M3 Emerging Medical Research, LLC	Durham	North Carolina
United States	Tri West Research Associates	El Cajon	California
United States	Methodist Physicians Clinic/ CCT Researc	Fremont	Nebraska
United States	Arizona Arthritis & Rheumatology Research	Glendale	Arizona
United States	PCPMG Clinical Research Unit, LLC	Greenville	South Carolina
United States	Klein & Associates, MD, PA	Hagerstown	Maryland
United States	Horizon Clinical Research Center	La Mesa	California
United States	Physician Research Collaboration	Lincoln	Nebraska
United States	Actca, A Member of the Allliance Inc.	Los Angeles	California
United States	University of California at Los Angeles	Los Angeles	California
United States	AMR Mobile	Mobile	Alabama
United States	Moore Orthopedics and Sports Medicine	Morehead City	North Carolina
United States	Affinity Health	Nashville	Tennessee
United States	Hospital for Special Surgery	New York	New York
United States	Lenox Hill Hospital (Northwell Health)	New York	New York
United States	NYU Langone Health	New York	New York
United States	Coastal Carolina Research Center	North Charleston	South Carolina
United States	Affinity Health	Oak Brook	Illinois
United States	M3 Emerging Medical Research, LLC	Raleigh	North Carolina
United States	Stanford Medicine	Redwood City	California
United States	University of California at Davis	Sacramento	California
United States	Gulfcoast Research Institute	Sarasota	Florida
United States	University Orthopedic Center	State College	Pennsylvania
United States	Pinnacle Trials, Inc.	Stockbridge	Georgia
United States	Fiel Family & Sports Medicine/ CCT Research	Tempe	Arizona
United States	Arizona Arthritis & Rheumatology Research	Tucson	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Organogenesis	Premier Research Group plc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The difference in change from baseline in WOMAC Pain scale at 6 months between ASA- and placebo-treated patients	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 26
Secondary	The difference between changes from baseline for ASA- and placebo- treated patients in WOMAC Function at 6 months	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 26
Secondary	The difference between changes from baseline for ASA- and placebo-treated patients in the OMERACT-OARSI responder rate at 6 months	Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International. (OMERACT-OARSI) Responders are defined as participants with high improvement in pain or function.	Baseline to Week 26
Secondary	The difference between changes from baseline for ASA- and placebo-treated patients in WOMAC Pain at 3 months	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 12
Secondary	The difference between changes from baseline for ASA- and placebo- treated patients in non-inferiority of WOMAC Function at 3 months	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 12
Secondary	The difference between changes from baseline for ASA- and placebo-treated patients in the OMERACT-OARSI responder rate at 3 months	Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International. (OMERACT-OARSI) Responders are defined as participants with high improvement in pain or function.	Baseline to Week 12
Secondary	The difference between changes from baseline for ASA- and placebo-treated patients in the WOMAC Total at 6 months	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 26
Secondary	The difference between ASA- and placebo-treated patients in the WOMAC Stiffness at 6 months	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 26
Secondary	The difference between changes from baseline for ASA- and placebo- treated patients in the WOMAC Total at 3 months	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 12
Secondary	The difference between changes from baseline for ASA- and placebo-treated patients in the WOMAC Stiffness at 3 months	The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Week 12
Secondary	Incidence of adverse events (AEs)	An AE is any untoward medical occurrence in a clinical study patient administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.; This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal result of diagnostic procedures, including clinical laboratory test abnormalities.	Baseline to Week 52

External Links

•   Farr J, et al. A randomized controlled single-blind study demonstrating superiority of ASA injection over hyaluronic acid and saline control for modification of knee OA symptoms. J Knee Surg. 2019; https://doi.org/10.1055/s-0039-1696672.